Regeneron Pharmaceuticals (REGN) director sells 100 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock in multiple open-market trades on May 1, 2026. The shares were sold at prices generally between about $701 and $714 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025. After these planned sales, he continues to hold a direct equity stake in the company.

Insider Trade Summary 10b5-1

Net Seller: 100 shares ($70,524)

Net Sell 12 txns

Insider RYAN ARTHUR F

Role null

Sold 100 shs ($71K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5	$701.76	$4K
Sale	Common Stock	15	$702.46	$11K
Sale	Common Stock	24	$703.46	$17K
Sale	Common Stock	15	$704.28	$11K
Sale	Common Stock	14	$705.56	$10K
Sale	Common Stock	7	$706.74	$5K
Sale	Common Stock	4	$707.40	$3K
Sale	Common Stock	6	$709.45	$4K
Sale	Common Stock	2	$710.87	$1K
Sale	Common Stock	5	$711.49	$4K
Sale	Common Stock	1	$712.09	$712.09
Sale	Common Stock	2	$714.13	$1K

Holdings After Transaction: Common Stock — 17,598 shares (Direct, null)

Footnotes (1)

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

Key Figures

Shares sold: 100 shares Highest reported sale price: $714.14 per share Lowest reported sale price: $701.36 per share +2 more

5 metrics

Shares sold 100 shares Total open-market sales on May 1, 2026

Highest reported sale price $714.14 per share Volume-weighted sale range footnote on May 1, 2026

Lowest reported sale price $701.36 per share Volume-weighted sale range footnote on May 1, 2026

Rule 10b5-1 plan adoption date October 31, 2025 Plan governing the May 1, 2026 sales

Transaction count 12 separate sale entries Non-derivative open-market sales of common stock

Key Terms

Rule 10b5-1(c), volume-weighted average price, Common Stock, open-market sale

4 terms

Rule 10b5-1(c) regulatory

"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

volume-weighted average price financial

"Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026..."

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

Common Stock financial

"security_title: Common Stock, transaction_type: non-derivative"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RYAN ARTHUR F

(Last)

(First)

(Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN

NEW YORK

10591

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		S⁽¹⁾		5	D	$701.76⁽²⁾	17,598	D
Common Stock	05/01/2026		S⁽¹⁾		15	D	$702.46⁽³⁾	17,583	D
Common Stock	05/01/2026		S⁽¹⁾		24	D	$703.46⁽⁴⁾	17,559	D
Common Stock	05/01/2026		S⁽¹⁾		15	D	$704.28⁽⁵⁾	17,544	D
Common Stock	05/01/2026		S⁽¹⁾		14	D	$705.56⁽⁶⁾	17,530	D
Common Stock	05/01/2026		S⁽¹⁾		7	D	$706.74⁽⁷⁾	17,523	D
Common Stock	05/01/2026		S⁽¹⁾		4	D	$707.4⁽⁸⁾	17,519	D
Common Stock	05/01/2026		S⁽¹⁾		6	D	$709.45⁽⁹⁾	17,513	D
Common Stock	05/01/2026		S⁽¹⁾		2	D	$710.87⁽¹⁰⁾	17,511	D
Common Stock	05/01/2026		S⁽¹⁾		5	D	$711.49⁽¹¹⁾	17,506	D
Common Stock	05/01/2026		S⁽¹⁾		1	D	$712.09	17,505	D
Common Stock	05/01/2026		S⁽¹⁾		2	D	$714.13⁽¹²⁾	17,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.

2. Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

8. Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

9. Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

10. Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

11. Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

12. Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

	/s/ Arthur F. Ryan	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Regeneron (REGN) disclose for Arthur F. Ryan?

Regeneron disclosed that director Arthur F. Ryan sold 100 shares of common stock in multiple open-market transactions on May 1, 2026. These trades were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on October 31, 2025.

How many Regeneron (REGN) shares did Arthur F. Ryan sell and at what prices?

Arthur F. Ryan sold a total of 100 Regeneron common shares. Footnotes show volume-weighted average sale prices in small blocks, with individual trades executed at prices ranging from about $701.36 to $714.14 per share on May 1, 2026.

Was Arthur F. Ryan’s Regeneron (REGN) stock sale under a Rule 10b5-1 plan?

Yes. The filing states the disposition was made under a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. Such plans pre-schedule trades, which makes the timing more routine and less about short-term market views.

What type of security did Arthur F. Ryan trade in this Regeneron (REGN) Form 4?

All reported transactions involved Regeneron common stock as a non-derivative security. The Form 4 shows only open-market sales of common shares, with no option exercises, derivative conversions, or tax-withholding entries reported in this particular filing.

Does Arthur F. Ryan still hold Regeneron (REGN) shares after these sales?

Yes. The Form 4 notes direct ownership of Regeneron common stock following the reported transactions. While exact post-transaction holdings vary across line items, the filing confirms he continues to maintain a direct equity position in the company.